Private label OTC maker building new South Carolina plant, to add 450 jobs

New York-based PL Developments will build a second manufacturing site in South Carolina.

PL Developments, a specialist of private label OTC products, will build a second manufacturing site in South Carolina, adding up to 450 jobs when it is complete.

The Westbury, New York, company will invest about $45 million in the new logistics and manufacturing center in Piedmont, South Carolina, with the help of a $750,000 grant from Greenville County for site improvements. This will be the company’s sixth U.S. site.

The logistics operations are slated to be up and operating next year and the product manufacturing is expected be online in 2018.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

“Opening a sixth production site has been a strategic objective for nearly two years,” PL Developments President Evan Singer said in a statement. “Longer term, the company has several growth initiatives which will be made feasible through the investments made at the site.”

PL Developments acquired its first site in the south in 2013 when the solid-dose maker of OTC products bought South Carolina-based Aaron Industries, a liquid product specialist. At the time, PL execs said the company’s compelling proposition was that it would be a strong competitor to market-dominant Perrigo.

PL Development built its expertise in packaging and distribution to meet the just-in-time requirements of a long list of large-box retail chain customers like Walmart, Costco, Walgreen's, CVS, Target, Dollar General and others. The company now produces about 450 products.

Suggested Articles

Fujifilm has completed the first manufacturing facility in Japan to make drug-delivering liposomes to use for cancer fighting drugs it is developing.

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.

The FDA has slapped a U.S. drug repackager, saying in a warning letter that its storage processes and equipment cleaning are not up to expectations.